PDCD1 and neoplasm: Moreover, the lower PDL1 expression in SUM159 cells treated with NExT (Fig. 3i) not only indicated interference of the nanoplatform with anti-PDL1 antibody binding to PDL1 on tumor cells but also suggested the disruption of the PD1/PDL1 axis.